moderate-to-severe primary axillary hyperhidrosis moderate, severe, primary, axillary hyperhidrosis
Conditions
Interventions
onabotulinumtoxinA 25 units per axilla,onabotulinumtoxinA 50 units per axilla
Experimental Drug,Experimental Drug
Low-dose,Standard-dose
Sponsors
WU grant, Walailak University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: -age 18 years or more -disease duration 6 months -moderate-to-severe severity -diagnosed with primary axillary hyperhidrosis
Exclusion criteria
Exclusion criteria: -diagnosed with secondary hyperhidrosis such as such as hyperthyroidism, concomitant therapy for hyperhidrosis, intake of drugs affecting muscle tone or the autonomic nervous system, pregnancy, or presence of malignancy. -contraindication to injected botulinum toxin such as keloidal scars, neuromuscular disorders, botulinum toxin allergies, body dysmorphic disorder, pregnancy, lactation, or amyotrophic lateralizing sclerosis myopathies -allergic history of povidone iodine, corn starch, 2% chlorhexidine in 70% isopropyl alcohol -bleeding disorder or currently used anti-coagulants -previously treated with botulinum toxin axillary injection in the past 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hyperhidrosis at 2 weeks and 12 weeks after end of the intervention Hyperhidrosis Disease Severity Scale (HDSS),Sweat production at 2 weeks, 4 weeks, and 12 weeks after end of the intervention weight (mg) per minute | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain within one day after end of the intervention pain score,Quality of life at 12 weeks after end of the intervention Hyperhidrosis Quality of Life Index,Patient satisfaction at 12 weeks after end of the intervention global self-assessment scale | — |
Countries
Thailand
Contacts
Public ContactWeeratian Tawanwongsri
Walailak University
Outcome results
None listed